

Subject Index

A

actively transcribed genes 169
adaptor 145, 146, 159
– bifunctional soluble 145, 146, 159
adenoviral vectors 246
African primates 70
AIDS 172, 230
aliphoid repeats 171
Alu 170, 171
– islands 170
– repeats 170, 171
amphotropic envelope 40
animal models 67, 69
anti-HIV gene(s) 230
– therapy 251
aphidicolin 65
arylsulfatase (ASA) 202
avian
– leukosis virus integration 170
– retroviruses 170
– virus 174
AZT 64, 65

B

bent DNA 169
BIF, vectors 85
biodistribution 159
biosafety 59, 60, 66, 67, 69, 70, 99, 123–137, 247
BIV, pathogenesis 79
budding 166, 172

C

CA 8
CAEV
– pathogenesis 79
– vectors 83, 86
capsid 5
CCR5 11
cDNA (complementary DNA) 165
293 cells 63, 110
central DNA flap 92
central nervous system 248

– diseases 191
centromeres 170
centromeric aliphoid repeats 170
c-fps/c-fes 172
cGMP phosphodiesterase β subunit 202
ciliary neurotrophic factor (CNTF) 203
circles 7
cis 184
CNS (*see* central nervous system)
CNTF (ciliary neurotrophic factor) 203
complementation 69
consensus sequence 167
CpG islands 169
cPPT 57, 59, 92, 94
CPPT/CTS 90
cross-packaging 66, 68
CTE 61, 90
CTS 57, 59
CXCR4 11
cyclophilin A 11

D

dentritic cells 65
disease models 47
DNA
– binding protein 167
– distortion 175
– flap model 22, 23
– major groove 169
– nucleosomal 175
– repair enzymes 167
– silent mating cassette 175
– torsional rigidity 172
– viral genomic 165
DNase I hypersensitive sites 169
dUTPase 93

E

EIAV 98
– pathogenesis 79
– vectors 84, 85
endogenous retroviruses 59, 68, 69
env 1

envelope expression 114
ERV 68

F

feline immunodeficiency virus (FIV) 96–98, 248
– derived lentiviral vectors 248
– pathogenesis 79
– vectors 84
finger proteins 173
fusion 3
– proteins 172

G

Gag 17
Gag-Pol polyproteins 172
Gag/Pol expression 113
gag 1
gag-pol precursor 166
galactosyltransferase 109
GALV 64, 65
Gap repair 166
GDNF (glial cell line-derived neurotrophic factor) 204, 205
gene(s) 143–146
– actively transcribed 169
– “augmentation” 251
– delivery 143, 144
– β -globin 158
– therapy 143, 144, 146, 229–240
– transfer 144–146
GFP 68
glial cell line-derived neurotrophic factor (GDNF) 204, 205, 249
 β -glucuronidase (GUS) 202

H

haploid 174
hematopoietic stem cells 45, 231, 250
hemophilia 99
hepatitis B virus (*see also* HPRE) 184
HERV (human endogenous retroviruses) 126
heterozygous virions 59, 61, 66, 67
hHSC 215
HIV
– infection 230
– integrase-lexA 174
HIV-1 1
– derived vectors
– – early 38
– – for gene therapy 38–45
– – lentiviral 248
– genome 32
– integrase 172
– lifecycle 32–37

HIV-2 1, 44
– derived lentiviral vectors 248
homotrimeric 156
host DNA repair system 166
hotspots 170, 173
– for integration 167
HTLV-1 171
human endogenous retroviruses (HERV) 126
Huntington's disease 192
hydroxyl groups 166

I

IHF protein 167
IN-zif 173
infection 172
– using lentiviral vectors 91–95
INS 57, 61, 62
insertional
– activation of oncogenes 172
– mutagenesis 172
integrase 6, 166
– model 18, 19
– protein 166
integration 3
interleukin-6 (IL-6) 203
introns 183
irradiation 65

J

JDV
– pathogenesis 79
– vectors 83, 85

L

LCR 158
LEF protein 167
lentivectors, improving biosafety 129–134
lentiviral
– replication cycle 17, 18
lentiviral vector(s) 172, 231, 246–248
– transduction of hematopoietic cells 231
– FIV-derived 248
– HIV-1-derived 248
– HIV-2-derived 248
– SIV-derived 248
– tropism 194
lentivirus(es) 246
– vectors, production 107–119
lexA DNA binding domain 174
LINE 170, 171
– elements 171
LINE-1 170
linker 151, 155–157
liver 251
locus control region 158

- long terminal repeat (LTR) 1, 166
 - promoter replacements 87
- looping 172
- lympho-hematological disorders 211–222
- lymphocytes 46
- lysosomal storage diseases 192, 248, 249
- M**
- MA 4
- macaque 66, 70, 232
- macrophage 13
- manufacturing 123
- matrix 4
- membranes 165
- metachromatic leukodystrophy (ML) 202, 249
- MLV 5
- Moloney* murine leukemia 169
- monocytes 13, 65
- mucopolysaccharidosis type VII 202, 248
- N**
- neurodegenerative diseases 192
- neurotropism 198
- NOD/SCID model 232
- non-*Hodgkin* lymphoma 172
- nonprimate
 - lentiviral vectors 76–100
 - lentiviruses, diseases 78
- nuclear export signal (NES) 180
- nuclear transport 37
- nucleic acid, removal 117
- nucleocapsid (NC) 8
- nucleosomal
 - DNA 175
 - templates 168
- nucleosomes 167
- O**
- oncogenes, insertional activation 172
- oncoretroviruses 6, 246
- open chromatin 170
 - regions 169
- λ operators 172
- P**
- packaging
 - cell line 45
 - cells 58, 60
 - constructs 60, 63, 67
 - genomes 61, 66
 - sequence 58, 66
 - systems 247
 - vectors 59
- packing signal 32
- Parkinson's* disease 192, 249
- PBMC 68
- PBS (primer-binding site) 32, 57–59
- PCR 170
- phage λ repressor 172
- phosphodiester-bonds 166
- PIC (*see* preintegration complex)
- pol* 1
- Pol III transcribed genes 175
- post-transcriptional regulatory element 43
- PPT 58, 59
- 3'PPT 57
- preintegration complex (PIC) 3, 165, 173
- primary sequence 175
- primate 69
 - lentivirus genome, nuclear uptake models 14–23
- primer-binding site (PBS) 32
- promoter 157, 158, 219, 220
 - regulatable 157, 158
 - tetracycline-inducible 158
- protease 8, 156, 157
 - factor Xa 156
 - MMP 156, 157
 - plasminogen activator 156
- provirus 166
- pseudotyping 145–147, 159
 - vesicular stomatitis virus G 246
- Q**
- quiescent T cells 12
- R**
- RD114 64
- recombinant retroviruses 61
- recombination 38, 66–69, 247
- replication-competent
 - retrovirus (RCR) 38, 59, 62, 63, 67, 68, 125, 126
 - vectors 58
- replication-defective vectors 58, 67, 247
- retina degeneration 192, 250
- retinitis pigmentosa 250
- retroviral
 - cDNA integration 165
 - vectors 246
- retroviruses 246
 - recombinant 61
 - replication-competent 59, 67
- Rev 2, 56–58, 60, 62, 63, 89, 181–183
 - responsive element 8
- reverse
 - transcriptase 166
 - transcription 3, 6, 36, 92
- RNA transport elements 89
- λ R-IN fusion 172
- RRE 2, 57, 59–62

S

- safety issues 123
- self-inactivating (SIN) 42, 218
 - vectors 41, 62, 116, 247
- sequestration 150, 152, 154, 156
- silent mating cassette DNA 175
- simian immunodeficiency virus (SIV) 1, 248
 - derived lentiviral vectors 248
- SIVmac239 61, 70
- SIVmac251 61, 66, 70
- SIVmacagm 61
- skeletal muscle 252
- stable packaging cell lines 133
- start site 175
- stem cell therapy 96
- steric hindrance 150
- strand transfer 166
- SupT1 170

T

- TAR 8, 56, 60–62
- target site commitment 174
- targeting 144–159
 - host range
 - - extension 148–152
 - - restriction 148, 152, 153
 - inverse 153–155, 159
 - protease 153, 155–157, 159
 - selective 152–154
 - transductional 146, 147, 157, 159
 - transcriptional 146, 157–159
- Tat 2, 56, 58, 60–63, 68
- tat-dependent vectors 233
- telomeres 175
- terminal cleavage 166
- tethering 172
 - molecular 154
- tetracycline (Tet)-regulated system 158
- β -thalassemia 251
- topoisomerase-cleavage sites 170
- torsional rigidity of DNA 172
- transcriptional
 - activator 170
 - silencing 246
- transfer vector 58, 59, 67
- transgenic mouse models 191
- transient transfection 111–113
- transposons 169
- Ty retrotransposons 174
- Ty1 integrates 174
- Ty3 175
- Ty5 175

U

- uncoating 3, 36

V

- vector 144–148, 150–159
 - adenoviral 246
 - chimeric 150, 152
 - gene transfer 144
 - injectable 144, 159
 - lentiviral 144, 145, 157–159, 246
 - lentivirus based 147, 157, 158
 - mobilization 60
 - nonprimate lentiviral 76–100
 - oncoretroviral 145
 - replication-competent 58
 - replication-defective 58, 67, 247
 - retroviral 146, 147, 150, 152, 153, 155, 246
 - retrovirus 146
 - self-inactivating 247
 - targetable 144, 159
 - viral 147, 148
- Vif 2
- viral
 - core 165
 - genomic DNA 165
 - protease 166
 - protein synthesis 34
 - replication cycle 8, 9
 - virion infectivity 9–11
- VMV, pathogenesis 78
- vpr fusion 174
- Vpr/Vpx 3, 4, 19
- VSV-G 39, 62, 64, 68

W

- woodchuck hepatitis virus (WPRE) 43, 90, 95, 184–186

X

- X-linked severe combined immunodeficiency 250

Y

- yeast life cycle 174

Z

- Zif268 173
- zinc-finger protein 173